No Data
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
List of cloud breakout stocks (Part 1) [Ichimoku Kinko Hyo Cloud Breakout Stock List]
○List of breakout stocks in the market Code Stock Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Prime ＜1808＞ Haseko 1882 1877.25 1754 ＜1861＞ Kumagai Gumi 3600 3583.75 3365 ＜1884＞ Nichidoro 1715 1708.25 1600 ＜1925＞ Daiwa House 4627 4564.54 158.5 ＜1942＞ Kandenko 2285 2196.25
ADR Japan stock ranking ~ Yucho Bank and others are generally selling more, Chicago is 365 yen cheaper than Osaka at 39,135 yen ~
Japanese stocks of American Depositary Receipts (ADRs) such as Yucho Bank <7182>, Hitachi Ltd sponsored ADR <6501>, Toyoda Automatic Loom Works <6201>, Renesas <6723>, Tokyo Electron <8035>, Toyota Motor <7203>, Honda Motor <7267>, etc., declined compared to the Tokyo Stock Exchange (converted at 152.58 yen per dollar), leading to overall selling pressure. The Chicago Nikkei 225 Futures settlement price was 365 yen lower at 39,135 yen compared to Osaka daytime trading. The US stock market is rising. The Dow Jones Industrial Average is up 259.65 dollars.
Application for partial change approval in Japan for the combination therapy of Vectibix intravenous drip and Lumakras tablets for unresectable advanced or recurrent colorectal cancer with KRAS G12C mutation.
On November 8, 2024, our company today filed for partial changes in manufacturing and marketing approval in japan for use of a combination therapy of Vectibix intravenous drip and Lumakras tablets in the treatment of KRAS G12C mutation-positive unresectable advanced recurrent colorectal cancer. Vectibix intravenous drip (generic name: panitumumab (recombinant DNA), hereinafter referred to as "Vectibix") for KRAS G12C mutation-positive unresectable advanced recurrent colorectal cancer.
Takeda (TAK.US) has initiated two Phase 3 clinical trials in china, launching innovative therapies for the disease of "excessive sleep".
TAK-861 is an oral orexin receptor 2 (OX2R) agonist. The product has been previously included in the breakthrough therapy category for the treatment of type 1 narcolepsy (NT1) by the China NMPA, as well as receiving breakthrough therapy designation from the FDA in the usa for the excessive daytime sleepiness associated with NT1.
Nikkei Stock Average Contribution Ranking (pre-closing) - The Nikkei average continued to rise significantly, with Advantest pushing up about 155 yen per share alone.
The number of rising stocks in the Nikkei average constituent stocks at the closing six days ago was 206 stocks up, 18 stocks down, and 1 stock unchanged. The Nikkei average continued to rise significantly. It closed the morning session at 39,341.44 yen, up 866.54 yen (+2.25%) from the previous day, with an estimated volume of 1,040 million shares traded. The U.S. market on the 5th day was up. The Dow Jones Average closed at 42,221.88 yen, up 427.28 yen, and the Nasdaq closed at 18,439.17, up 259.19 points. Through the presidential election.
No Data
No Data
